• Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023

    المصدر: Nasdaq GlobeNewswire / 31 أكتوبر 2023 15:02:00   America/Chicago

    BURLINGAME, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 7, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2023 financial results.

    The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website.   A replay of the webcast will be available on Corvus’ website for 90 days.

    About Corvus Pharmaceuticals
    Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Corvus plans to initiate a Phase 3 registrational clinical trial for soquelitinib in patients with relapsed peripheral T cell lymphoma. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.

    INVESTOR CONTACT:
    Leiv Lea
    Chief Financial Officer
    Corvus Pharmaceuticals, Inc.
    +1-650-900-4522
    llea@corvuspharma.com

    MEDIA CONTACT:
    Sheryl Seapy
    Real Chemistry
    +1-949-903-4750
    sseapy@realchemistry.com


    Primary Logo

شارك على،